Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, announced today the commercial launch in Denmark of Wynzora® cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate), developed for the topical treatment of mild to moderate plaque psoriasis in adults including .